vs

Side-by-side financial comparison of AMES NATIONAL CORP (ATLO) and Avidity Biosciences, Inc. (RNA). Click either name above to swap in a different company.

AMES NATIONAL CORP is the larger business by last-quarter revenue ($18.7M vs $12.5M, roughly 1.5× Avidity Biosciences, Inc.). AMES NATIONAL CORP runs the higher net margin — 34.9% vs -1398.3%, a 1433.2% gap on every dollar of revenue. On growth, Avidity Biosciences, Inc. posted the faster year-over-year revenue change (434.0% vs 26.7%). AMES NATIONAL CORP produced more free cash flow last quarter ($20.7M vs $-156.9M). Over the past eight quarters, Avidity Biosciences, Inc.'s revenue compounded faster (138.5% CAGR vs 19.5%).

Ames National Corp is a U.S. financial holding company based in Iowa. It operates multiple community banking subsidiaries, offering retail and commercial financial services including deposit accounts, personal and business loans, mortgages, and wealth management, primarily serving consumers and SMEs across central Iowa.

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named.

ATLO vs RNA — Head-to-Head

Bigger by revenue
ATLO
ATLO
1.5× larger
ATLO
$18.7M
$12.5M
RNA
Growing faster (revenue YoY)
RNA
RNA
+407.4% gap
RNA
434.0%
26.7%
ATLO
Higher net margin
ATLO
ATLO
1433.2% more per $
ATLO
34.9%
-1398.3%
RNA
More free cash flow
ATLO
ATLO
$177.6M more FCF
ATLO
$20.7M
$-156.9M
RNA
Faster 2-yr revenue CAGR
RNA
RNA
Annualised
RNA
138.5%
19.5%
ATLO

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ATLO
ATLO
RNA
RNA
Revenue
$18.7M
$12.5M
Net Profit
$6.5M
$-174.4M
Gross Margin
Operating Margin
44.3%
-1513.5%
Net Margin
34.9%
-1398.3%
Revenue YoY
26.7%
434.0%
Net Profit YoY
85.4%
-117.0%
EPS (diluted)
$-1.27

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ATLO
ATLO
RNA
RNA
Q4 25
$18.7M
Q3 25
$16.6M
$12.5M
Q2 25
$16.1M
$3.8M
Q1 25
$15.5M
$1.6M
Q4 24
$14.7M
$3.0M
Q3 24
$13.5M
$2.3M
Q2 24
$13.5M
$2.0M
Q1 24
$13.1M
$3.5M
Net Profit
ATLO
ATLO
RNA
RNA
Q4 25
$6.5M
Q3 25
$4.6M
$-174.4M
Q2 25
$4.5M
$-157.3M
Q1 25
$3.4M
$-115.8M
Q4 24
$3.5M
$-102.3M
Q3 24
$2.2M
$-80.4M
Q2 24
$2.2M
$-70.8M
Q1 24
$2.3M
$-68.9M
Operating Margin
ATLO
ATLO
RNA
RNA
Q4 25
44.3%
Q3 25
34.5%
-1513.5%
Q2 25
35.0%
-4448.7%
Q1 25
27.4%
-8360.9%
Q4 24
29.4%
-4069.6%
Q3 24
19.4%
-4200.9%
Q2 24
19.0%
-4040.4%
Q1 24
20.8%
-2178.6%
Net Margin
ATLO
ATLO
RNA
RNA
Q4 25
34.9%
Q3 25
27.5%
-1398.3%
Q2 25
28.0%
-4089.3%
Q1 25
22.3%
-7360.0%
Q4 24
23.8%
-3439.5%
Q3 24
16.4%
-3441.7%
Q2 24
16.2%
-3461.8%
Q1 24
17.6%
-1943.4%
EPS (diluted)
ATLO
ATLO
RNA
RNA
Q4 25
Q3 25
$-1.27
Q2 25
$-1.21
Q1 25
$-0.90
Q4 24
$-0.80
Q3 24
$-0.65
Q2 24
$-0.65
Q1 24
$-0.79

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ATLO
ATLO
RNA
RNA
Cash + ST InvestmentsLiquidity on hand
$126.8M
$350.2M
Total DebtLower is stronger
$18.4M
Stockholders' EquityBook value
$207.9M
$1.9B
Total Assets
$2.1B
$2.1B
Debt / EquityLower = less leverage
0.09×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ATLO
ATLO
RNA
RNA
Q4 25
$126.8M
Q3 25
$108.2M
$350.2M
Q2 25
$95.2M
$243.9M
Q1 25
$163.4M
$254.2M
Q4 24
$101.2M
$219.9M
Q3 24
$59.0M
$370.2M
Q2 24
$63.4M
$575.8M
Q1 24
$111.4M
$471.4M
Total Debt
ATLO
ATLO
RNA
RNA
Q4 25
$18.4M
Q3 25
Q2 25
Q1 25
Q4 24
$20.0M
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ATLO
ATLO
RNA
RNA
Q4 25
$207.9M
Q3 25
$200.6M
$1.9B
Q2 25
$193.0M
$1.2B
Q1 25
$183.1M
$1.3B
Q4 24
$174.7M
$1.4B
Q3 24
$183.4M
$1.5B
Q2 24
$167.1M
$1.2B
Q1 24
$165.5M
$830.9M
Total Assets
ATLO
ATLO
RNA
RNA
Q4 25
$2.1B
Q3 25
$2.1B
$2.1B
Q2 25
$2.1B
$1.4B
Q1 25
$2.2B
$1.5B
Q4 24
$2.1B
$1.6B
Q3 24
$2.1B
$1.6B
Q2 24
$2.1B
$1.3B
Q1 24
$2.2B
$951.5M
Debt / Equity
ATLO
ATLO
RNA
RNA
Q4 25
0.09×
Q3 25
Q2 25
Q1 25
Q4 24
0.11×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ATLO
ATLO
RNA
RNA
Operating Cash FlowLast quarter
$21.3M
$-156.2M
Free Cash FlowOCF − Capex
$20.7M
$-156.9M
FCF MarginFCF / Revenue
110.8%
-1257.6%
Capex IntensityCapex / Revenue
3.4%
5.7%
Cash ConversionOCF / Net Profit
3.28×
TTM Free Cash FlowTrailing 4 quarters
$34.2M
$-592.3M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ATLO
ATLO
RNA
RNA
Q4 25
$21.3M
Q3 25
$2.8M
$-156.2M
Q2 25
$4.0M
$-199.7M
Q1 25
$7.1M
$-124.8M
Q4 24
$14.3M
$-99.9M
Q3 24
$3.1M
$-65.6M
Q2 24
$3.9M
$-65.0M
Q1 24
$1.4M
$-70.4M
Free Cash Flow
ATLO
ATLO
RNA
RNA
Q4 25
$20.7M
Q3 25
$2.6M
$-156.9M
Q2 25
$3.9M
$-203.0M
Q1 25
$6.9M
$-128.6M
Q4 24
$14.0M
$-103.8M
Q3 24
$3.0M
$-67.3M
Q2 24
$3.8M
$-65.5M
Q1 24
$1.3M
$-71.3M
FCF Margin
ATLO
ATLO
RNA
RNA
Q4 25
110.8%
Q3 25
16.0%
-1257.6%
Q2 25
24.2%
-5277.1%
Q1 25
44.8%
-8174.3%
Q4 24
94.9%
-3491.0%
Q3 24
22.5%
-2881.8%
Q2 24
28.1%
-3204.6%
Q1 24
10.0%
-2012.3%
Capex Intensity
ATLO
ATLO
RNA
RNA
Q4 25
3.4%
Q3 25
0.6%
5.7%
Q2 25
0.7%
86.9%
Q1 25
1.3%
238.6%
Q4 24
2.0%
131.7%
Q3 24
0.5%
72.9%
Q2 24
0.7%
26.0%
Q1 24
0.5%
25.8%
Cash Conversion
ATLO
ATLO
RNA
RNA
Q4 25
3.28×
Q3 25
0.60×
Q2 25
0.89×
Q1 25
2.07×
Q4 24
4.07×
Q3 24
1.40×
Q2 24
1.78×
Q1 24
0.59×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons